ECSP19056271A - Dendrímeros terapéuticos - Google Patents

Dendrímeros terapéuticos

Info

Publication number
ECSP19056271A
ECSP19056271A ECSENADI201956271A ECDI201956271A ECSP19056271A EC SP19056271 A ECSP19056271 A EC SP19056271A EC SENADI201956271 A ECSENADI201956271 A EC SENADI201956271A EC DI201956271 A ECDI201956271 A EC DI201956271A EC SP19056271 A ECSP19056271 A EC SP19056271A
Authority
EC
Ecuador
Prior art keywords
dendrimers
therapeutic
formula
disclosed
dendrimer
Prior art date
Application number
ECSENADI201956271A
Other languages
English (en)
Inventor
Iain Grant
John Secrist
Brian Kelly
David Owen
William Mccoull
Michael Giannis
Edward Hennessy
Marianne Ashford
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ECSP19056271A publication Critical patent/ECSP19056271A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/641—Branched, dendritic or hypercomb peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10—Alpha-amino-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/40—Polyamides containing oxygen in the form of ether groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • C08G83/002—Dendritic macromolecules
    • C08G83/003—Dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Prostheses (AREA)
  • Pyridine Compounds (AREA)

Abstract

Se divulgan dendrímeros de fórmula (I): y sales farmacéuticamente aceptables de los mismos. También se divulgan composiciones farmacéuticas que comprenden el dendrímero de fórmula (I) y métodos para usar los mismos para el tratamiento del cáncer.
ECSENADI201956271A 2017-02-22 2019-08-06 Dendrímeros terapéuticos ECSP19056271A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762461983P 2017-02-22 2017-02-22
US201762488151P 2017-04-21 2017-04-21
US201762591823P 2017-11-29 2017-11-29

Publications (1)

Publication Number Publication Date
ECSP19056271A true ECSP19056271A (es) 2019-08-30

Family

ID=61386833

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI201956271A ECSP19056271A (es) 2017-02-22 2019-08-06 Dendrímeros terapéuticos

Country Status (23)

Country Link
US (4) US10314920B2 (es)
EP (1) EP3585441A1 (es)
JP (1) JP7074761B2 (es)
KR (2) KR20230093346A (es)
CN (2) CN110312531A (es)
AU (1) AU2018223149B2 (es)
BR (1) BR112019016409A2 (es)
CA (1) CA3053069A1 (es)
CL (1) CL2019002240A1 (es)
CO (1) CO2019009722A2 (es)
CR (1) CR20190361A (es)
DO (1) DOP2019000204A (es)
EC (1) ECSP19056271A (es)
IL (1) IL268648B (es)
JO (1) JOP20190191A1 (es)
MX (1) MX2019009442A (es)
NI (1) NI201900088A (es)
PE (1) PE20191660A1 (es)
PH (1) PH12019501896A1 (es)
SG (1) SG11201907334QA (es)
TW (1) TWI773730B (es)
UA (1) UA125655C2 (es)
WO (1) WO2018154004A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190191A1 (ar) * 2017-02-22 2019-08-08 Astrazeneca Ab وحدات شجرية علاجية
TWI831817B (zh) * 2018-08-17 2024-02-11 瑞典商阿斯特捷利康公司 治療癌症之方法
CN112543664A (zh) * 2018-08-17 2021-03-23 阿斯利康(瑞典)有限公司 树枝状体配制品
JP7550149B2 (ja) * 2018-11-20 2024-09-12 スターファーマ ピーティーワイ エルティーディー 治療用デンドリマー
EP3965567B1 (en) 2019-05-07 2023-07-05 Syddansk Universitet Mechanism for dispensing biological material
JP2022549680A (ja) * 2019-09-26 2022-11-28 スターファーマ ピーティーワイ エルティーディー 治療用デンドリマー
US20210170040A1 (en) * 2019-12-04 2021-06-10 Ashvattha Therapeutics, Inc. Dendrimer compositions and methods for drug delivery
WO2021213492A1 (zh) * 2020-04-24 2021-10-28 上海森辉医药有限公司 一类载药的大分子及其制备方法
AU2021259877A1 (en) 2020-04-24 2022-12-08 Ashvattha Therapeutics, Inc. Dendrimer compositions and methods for treatment of severe acute respiratory distress syndrome
WO2022007940A1 (zh) * 2020-07-10 2022-01-13 江苏恒瑞医药股份有限公司 磺酰苯甲酰胺类衍生物及其偶联物、其制备方法及其应用
WO2022042583A1 (zh) 2020-08-25 2022-03-03 上海森辉医药有限公司 载药的大分子及其制备方法
WO2022040761A1 (en) * 2020-08-31 2022-03-03 Starpharma Pty Ltd Dendrimer-drug conjugate

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4289872A (en) * 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
US4410688A (en) * 1981-04-29 1983-10-18 Allied Corporation Macromolecular highly branched homogeneous compound
US6720338B2 (en) 2000-09-20 2004-04-13 Abbott Laboratories N-acylsulfonamide apoptosis promoters
UY26942A1 (es) 2000-09-20 2002-04-26 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
PL2757099T3 (pl) 2005-05-12 2018-02-28 Abbvie Bahamas Limited Promotory apoptozy
HUE031341T2 (hu) * 2005-10-25 2017-07-28 Starpharma Pty Ltd Ellenõrzött sztöchiometriájú makromolekuláris vegyületek
JP5989294B2 (ja) 2006-01-20 2016-09-07 スターファーマ・プロプライエタリー・リミテッドＳｔａｒｐｈａｒｍａ Ｐｔｙ Ｌｔｄ 修飾高分子
WO2008017122A1 (en) * 2006-08-11 2008-02-14 Starpharma Pty Ltd Polylysine dendrimer contrast agent
US8420067B2 (en) * 2006-08-11 2013-04-16 Starpharma Pty Ltd Targeted polylysine dendrimer therapeutic agent
JP5366817B2 (ja) 2006-11-15 2013-12-11 ジェネンテック， インコーポレイテッド アリールスルホンアミド化合物
US9283302B2 (en) 2011-12-16 2016-03-15 Cormatrix Cardiovascular, Inc. Extracellular matrix encasement structures and methods
WO2009036035A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Bcl-2 inhibitors
WO2009158668A1 (en) 2008-06-26 2009-12-30 Prolynx Llc Prodrugs and drug-macromolecule conjugates having controlled drug release rates
US8216549B2 (en) * 2008-07-25 2012-07-10 National Health Research Institutes Method for making a ligand-quantum dot conjugate
BRPI0922771A2 (pt) 2008-12-05 2018-11-06 Abbott Lab agentes indutores de apoptose seletivos para bcl-2 para o tratamento de câncer e doenças imunes
KR102001418B1 (ko) 2009-05-26 2019-07-19 애브비 아일랜드 언리미티드 컴퍼니 암，면역 질환 및 자가면역 질환의 치료를 위한 아폽토시스-유도제
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI471321B (zh) 2009-06-08 2015-02-01 Abbott Gmbh & Co Kg Ｂｃｌ－２族群抑制劑之口服醫藥劑型
US20120269721A1 (en) * 2009-10-12 2012-10-25 The Regents Of The University Of California Targeted nanoclusters and methods of their use
EP2571496A4 (en) 2010-05-05 2016-03-30 Prolynx Llc CONTROLLED RELEASE OF MEDICINE FROM DENIMERS
US8754190B2 (en) 2010-05-05 2014-06-17 Prolynx Llc Controlled release from macromolecular conjugates
WO2011140392A1 (en) 2010-05-05 2011-11-10 Prolynx Llc Controlled drug release from solid supports
TWI535712B (zh) * 2010-08-06 2016-06-01 阿斯特捷利康公司 化合物
JP6158177B2 (ja) * 2011-06-06 2017-07-05 スターファーマ・ピーティーワイ・リミテッド 高分子
US20160220689A1 (en) * 2013-09-10 2016-08-04 Starpharma Pty Ltd. Macromolecules of dendrimer-platinum conjugates
WO2015184510A1 (en) * 2014-06-06 2015-12-10 Starpharma Pty Ltd Dendrimer-drug conjugates
JOP20190191A1 (ar) * 2017-02-22 2019-08-08 Astrazeneca Ab وحدات شجرية علاجية
TWI831817B (zh) * 2018-08-17 2024-02-11 瑞典商阿斯特捷利康公司 治療癌症之方法
CN112543664A (zh) * 2018-08-17 2021-03-23 阿斯利康(瑞典)有限公司 树枝状体配制品

Also Published As

Publication number Publication date
AU2018223149A1 (en) 2019-10-03
CL2019002240A1 (es) 2019-11-29
US10888624B2 (en) 2021-01-12
AU2018223149B2 (en) 2021-04-01
CR20190361A (es) 2019-09-24
SG11201907334QA (en) 2019-09-27
US20240115716A1 (en) 2024-04-11
US20210060172A1 (en) 2021-03-04
CO2019009722A2 (es) 2019-09-18
IL268648B (en) 2022-04-01
PH12019501896A1 (en) 2019-10-21
BR112019016409A2 (pt) 2020-04-07
JP7074761B2 (ja) 2022-05-24
TW201841659A (zh) 2018-12-01
IL268648A (en) 2019-10-31
KR20230093346A (ko) 2023-06-27
KR102544033B1 (ko) 2023-06-14
CN110312531A (zh) 2019-10-08
KR20190112330A (ko) 2019-10-04
US11717574B2 (en) 2023-08-08
WO2018154004A1 (en) 2018-08-30
UA125655C2 (uk) 2022-05-11
JOP20190191A1 (ar) 2019-08-08
CN117582521A (zh) 2024-02-23
PE20191660A1 (es) 2019-11-11
US20200069810A1 (en) 2020-03-05
JP2020508985A (ja) 2020-03-26
EP3585441A1 (en) 2020-01-01
MX2019009442A (es) 2019-10-09
NI201900088A (es) 2020-03-18
CA3053069A1 (en) 2018-08-30
US20180264127A1 (en) 2018-09-20
TWI773730B (zh) 2022-08-11
WO2018154004A9 (en) 2018-12-27
DOP2019000204A (es) 2019-08-30
US10314920B2 (en) 2019-06-11

Similar Documents

Publication Publication Date Title
CO2019009722A2 (es) Dendrímeros terapéuticos
CY1121413T1 (el) Διυδροπυρρολοπυριδινης αναστολεις ror-γαμμα
CO2019007863A2 (es) Derivados de benzooxazol como inmunomoduladores
NI201900062A (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
CL2018003701A1 (es) Compuestos heterocíclicos como inmunomoduladores.
CL2020002511A1 (es) Compuestos heterocíclicos como inmunomoduladores.
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
CL2020000501A1 (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos.
NI201600165A (es) Inhibidores de desmetilasa 1 específica a lisina
DOP2019000020A (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
UY37205A (es) Inhibidores de bromodominios
CL2017000992A1 (es) Compuestos de indol carboxamida utiles como inhibidores de cinasa
CR20170563A (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso.
SV2018005687A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer
CO2019009423A2 (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos
CL2021001388A1 (es) Compuestos útiles en la terapia para el vih
CO2018013828A2 (es) Composiciones farmacéuticas de oligómero de morfolino fósforodiamidato
UY36732A (es) Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet
AR111063A1 (es) Dendrímeros terapéuticos
EA201991924A1 (ru) Терапевтические дендримеры
CL2020002398A1 (es) Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida ("tcd")
CO2019001967A2 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
CR20190028A (es) Compuestos heterocíclicos como inmunomoduladores